Associations between antinuclear antibody staining patterns and clinical features of systemic lupus erythematosus: Analysis of a regional Swedish register

BMJ Open

Volumn 3, Issue 10, 2013, Pages

  Frodlund, Martina ^a   Dahlström, Örjan ^a   Kastbom, Alf ^a   Skogh, Thomas ^a   Sjöwall, Christopher ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; CELL NUCLEUS ANTIGEN; DOUBLE STRANDED DNA; JO 1 ANTIBODY; SCL 70 ANTIBODY; SMALL NUCLEAR RIBONUCLEOPROTEIN;

ADULT; AGED; ANTIGEN SPECIFICITY; ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; DISEASE REGISTRY; DNA EXTRACTION; FEMALE; HUMAN; IMMUNODIFFUSION; IMMUNOFLUORESCENCE MICROSCOPY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PHENOTYPE; STAINING; SWEDEN; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 84887946369     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-003608     Document Type: Article

References (53)

1. Lateef A, Petri M. Unmet medical needs in systemic lupus erythematosus. Arthritis Res Ther 2012;14(Suppl 4):S4.
2. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008;358:929-39. (Pubitemid 351397092)
3. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7. (Pubitemid 13221242)
4. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
5. Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012;64:2677-86.
6. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24. (Pubitemid 18091653)
7. Dahle C, Skogh T, Åberg AK, et al. Methods of choice for diagnostic antinuclear antibody (ANA) screening: benefit of adding antigen-specific assays to immunofluorescence microscopy. J Autoimmun 2004;22:241-8. (Pubitemid 38369185)
8. Sjöwall C, Sturm M, Dahle C, et al. Abnormal antinuclear antibody titers are less common than generally assumed in established cases of systemic lupus erythematosus. J Rheumatol 2008;35:1994-2000.
9. Solomon DH, Kavanaugh AJ, Schur PH, et al. Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum 2002;47:434-44. (Pubitemid 34856134)
10. von Mühlen CA, Tan EM. Autoantibodies in the diagnosis of systemic lupus erythematosus. Semin Arthritis Rheum 1995;5:323-58.
11. Mariz HA, Sato EI, Barbosa SH, et al. Pattern on the antinuclear antibody-HEp-2 test is a critical parameter for discriminating antinuclear antibody-positive healthy individuals and patients with autoimmune rheumatic diseases. Arthritis Rheum 2011;63:191-200.
12. Mahler M, Fritzler MJ. The clinical significance of the dense fine speckled immunofluorescence pattern on HEp-2 cells for the diagnosis of systemic autoimmune diseases. Clin Dev Immunol 2012;2012:494356.
13. Fritzler MJ. Clinical relevance of autoantibodies in systemic rheumatic diseases. Mol Biol Rep 1996;23:133-45. (Pubitemid 27153034)
14. ter Borg EJ, Horst G, Hummel EJ, et al. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus: a long-term, prospective study. Arthritis Rheum 1990;33:634-43. (Pubitemid 20166564)
15. Kavanaugh AF, Solomon DH; American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines. Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-DNA antibody tests. Arthritis Rheum 2002;47:546-55. (Pubitemid 35291379)
16. Isenberg DA, Manson JJ, Ehrenstein MR, et al. Fifty years of anti-ds DNA antibodies: are we approaching journey's end? Rheumatology (Oxford) 2007;46:1052-6. (Pubitemid 47050602)
17. Winfield JB, Brunner CM, Koffler D. Serologic studies in patients with systemic lupus erythematosus and central nervous system dysfunction. Arthritis Rheum 1978;21:289-94. (Pubitemid 9206914)
18. Janwityanuchit S, Verasertniyom O, Vanichapuntu M, et al. Anti-Sm: its predictive value in systemic lupus erythematosus. Clin Rheumatol 1993;12:350-3. (Pubitemid 23306870)
19. Wang CL, Ooi L, Wang F. Prevalence and clinical significance of antibodies to ribonucleoproteins in systemic lupus erythematosus in Malaysia. Br J Rheumatol 1996;35:129-32.
20. Alba P, Bento L, Cuadrado MJ, et al. Anti-dsDNA, anti-Sm antibodies and the lupus anticoagulant: significant factors associated with lupus nephritis. Ann Rheum Dis 2003;62:556-60. (Pubitemid 36606290)
21. Benito-Garcia E, Schur PH, Lahita R, et al. Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-Sm and anti-RNP antibody tests. Arthritis Rheum 2004;51:1030-44. (Pubitemid 39648199)
22. Thompson D, Juby A, Davis P. The clinical significance of autoantibody profiles in patients with systemic lupus erythematosus. Lupus 1993;2:15-19. (Pubitemid 23115233)
23. Hoffman IE, Peene I, Meheus L, et al. Specific antinuclear antibodies are associated with clinical features in systemic lupus erythematosus. Ann Rheum Dis 2004;63:1155-8. (Pubitemid 39120371)
24. Ching KH, Burbel PD, Tipton C, et al. Two major autoantibody clusters in systemic lupus erythomatousus. PLoS ONE 2012;7:e32001.
25. Bunn CC, Denton CP, Shi-Wen X, et al. Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis. Br J Rheumatol 1998;37:15-20.
26. Brouwer R, Vree Egberts WT, Hengstman GJ, et al. Autoantibodies directed to novel components of the PM/Scl complex, the human exosome. Arthritis Res 2002;4:134-8. (Pubitemid 34257347)
27. Sontheimer RD, Maddison PJ, Reichlin M, et al. Serologic and HLA associations in subacute cutaneous lupus erythematosus, a clinical subset of lupus erythematosus. Ann Intern Med 1982;97:664-71. (Pubitemid 13251635)
28. Anderson MJ, Peebles CL, McMillan R, et al. Fluorescent antinuclear antibodies and anti-SSA/Ro in patients with immune thrombocytopenia subsequently developing systemic lupus erythomatousus. Ann Intern Med 1985;103:548-50.
29. Mond CB, Peterson MG, Rothfield NF. Correlation of anti-Ro antibody with photosensitivity rash in systemic lupus erythomatousus patients. Arthritis Rheum 1989;32:202-4. (Pubitemid 19056408)
30. Baer AN, Maynard JW, Shaikh F, et al. Secondary Sjögren's syndrome in systemic lupus erythematosus defines a distinct disease subset. J Rheumatol 2010;37:1143-9.
31. Franceschini F, Cavazzana I. Anti-Ro/SSA and La/SSB antibodies. Autoimmunity 2005;38:55-63. (Pubitemid 40515004)
32. Fritzler MJ, Hanson C, Miller J, et al. Specificity of autoantibodies to SS-A/Ro on a transfected and overexpressed human 60 kDa Ro autoantigen substrate. J Clin Lab Anal 2002;16:103-8. (Pubitemid 34293089)
33. Buyon JP, Clancy RM, Friedman DM. Autoimmune associated congenital heart block: integration of clinical and research clues in the management of the maternal / foetal dyad at risk. J Intern Med 2009;265:653-62.
34. Oke V, Wahren-Herlenius M. The immunobiology of Ro52 (TRIM21) in autoimmunity: a critical review. J Autoimmun 2012;39:77-82.
35. Enocsson H, Wetterö J, Skogh T, et al. Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus. Transl Res 2013;162:287-96.
36. Fries JF, Holman HR. Systemic lupus erythematosus: a clinical analysis. In: Smith LH. ed. Major problems in internal medicine. Philadelphia, London, Toronto W.B: Sauners, 1975:8-20.
37. Fries JF. Methodology of validation of criteria for SLE. Scand J Rheumatol Suppl 1987;65:25-30.
38. Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996;39:363-9. (Pubitemid 26085211)
39. Churg J, Bernstein J, Glassock RJ. Renal disease: classification and atlas of glomerular diseases 2nd edn. New York: Igaku-Shoin, 1995.
40. Holman HR, Kunkel HG. Affinity between the lupus erythematosus serum factor and cell nuclei and nucleoprotein. Science 1957;126:162-3.
41. Friou GJ. Antinuclear antibodies: diagnostic significance and methods. Arthritis Rheum 1967;10:151-9.
42. Meroni PL, Schur PH. ANA screening: an old test with new recommendations. Ann Rheum Dis 2010;69:1420-2.
43. Proschan MA, Waclawiw MA. Practical guidelines for multiplicity adjustment in clinical trials. Control Clin Trials 2000;21:527-39. (Pubitemid 32056216)
44. Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009;61:1168-78.
45. Hochberg MC, Boyd RE, Ahearn JM, et al. Systemic lupus erythematosus: a review of clinico-laboratory features and immunogenetic markers in 150 patients with emphasis on demographic subsets. Medicine (Baltimore) 1985;64:285-95. (Pubitemid 16224044)
46. To CH, Petri M. Is antibody clustering predictive of clinical subsets and damage in systemic lupus erythematosus? Arthritis Rheum 2005;52:4003-10. (Pubitemid 41798240)
47. Boey ML, Peebles CL, Tsay G, et al. Clinical and autoantibody correlations in Orientals with systemic lupus erythematosus. Ann Rheum Dis 1988;47:918-23. (Pubitemid 18263863)
48. Sutej PG, Gear AJ, Morrison RC, et al. Photosensitivity and anti-Ro (SS-A) antibodies in black patients with systemic lupus erythematosus (SLE). Br J Rheumatol 1989;28:321-4. (Pubitemid 19205927)
49. Paz ML, González Maglio DH, Pino M, et al. Anti-ribonucleoproteins autoantibodies in patients with systemic autoimmune diseases. Relation with cutaneous photosensitivity. Clin Rheumatol 2011;30:209-16.
50. Li PH, Wong WH, Lee TL, et al. Relationship between autoantibody clustering and clinical subsets in SLE: cluster and association analyses in Hong Kong Chinese. Rheumatology (Oxford) 2013;52:337-45.
51. Stoll T, Seifert B, Isenberg DA. SLICC/ACR Damage Index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus. Br J Rheumatol 1996;35:248-54.
52. Rahman P, Gladman DD, Urowitz MB, et al. Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus. Lupus 2001;10:93-6. (Pubitemid 32410092)
53. Rullo OJ, Woo JM, Parsa MF, et al. Plasma levels of osteopontin identify patients at risk for organ damage in systemic lupus erythematosus. Arthritis Res Ther 2013;15:R18.